Optimi Health Corp. Common Shares OPTH

Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.

OPTH hizo una agrupación de acciones (split inverso) de 1:30 el 20 de mayo de 2026: cada 30 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 29 jun

  Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

  Optimi Health completed its third commercial shipment of 5mg psilocybin capsules to Australia, exporting 1,000 capsules for treatment-resistant depression patients. The company reports no serious adverse events since the September 2025 launch and notes expanding reimbursement coverage from both private and public insurers in Australia.

  

• Benzinga 18 jun

  SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets

  SRx Health Solutions has completed its acquisition of EMJ Crypto Technologies (EMJX) and rebranded as SRX Global Inc. The company is launching an AI-driven platform strategy focused on capital allocation into high-conviction operating companies and assets. The merged entity will be led by Kent Cunningham as CEO and Eric Jackson as President and Head of Asset Management, with initial investments in companies including Astro Capital, Opendoor Technologies, Uber Technologies, and Optimi Health Corp.

  

• Benzinga 16 jun

  Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

  Optimi Health Corp. announced the completion of two standardized microdose psilocybin finished drug products at 1mg and 2mg dosages for clinical research organizations. The products offer consistent, validated doses derived from naturally sourced psilocybin, extending Optimi's existing 5mg formulation currently prescribed for treatment-resistant depression in Australia. All production is conducted in-house at Optimi's GMP-compliant facility in British Columbia, Canada.